3 hours Ago By Defense World Staff
Victory Capital Management Inc. bought a new stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC).
The firm bought 268,076 shares of the company’s stock, valued at approximately $6,241,000. Victory Capital Management Inc. owned approximately 0.
52% of Spyre Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Other hedge funds and other institutional investors also recently made changes to their positions in the company. Barclays PLC increased its stake in shares of Spyre Therapeutics by 64.
7% in the third quarter. Barclays PLC now owns 105,467 shares of the company’s stock valued at $3,101,000 after buying an additional 41,424 shares in the last quarter. China Universal Asset Management Co.
Ltd. acquired a new stake in shares of Spyre Therapeutics in the fourth quarter valued at $290,000. Charles Schwab Investment Management Inc.
increased its stake in shares of Spyre Therapeutics by 239.4% in the third quarter. Charles Schwab Investment Management Inc.
now owns 333,275 shares of the company’s stock valued at $9,802,000 after buying an additional 235,094 shares in the last quarter. Jane Street Group LLC increased its stake in shares of Spyre Therapeutics by 78.7% in the third quarter.
Jane Street Group LLC now owns 20,641 shares of the company’s stock valued at $607,000 after buying an additional 9,090 shares in the last quarter. Finally, State Street Corp increased its stake in shares of Spyre Therapeutics by 9.4% in the third quarter.
State Street Corp now owns 1,541,555 shares of the company’s stock valued at $45,337,000 after buying an additional 131,896 shares in the last quarter. 80.39% of the stock is currently owned by institutional investors and hedge funds.
Spyre Therapeutics Trading Up 0.1 %Shares of SYRE opened at $18.04 on Friday.
Spyre Therapeutics, Inc. has a 1 year low of $17.24 and a 1 year high of $47.
97. The stock has a market cap of $1.09 billion, a P/E ratio of -2.
41 and a beta of 2.98. The stock’s 50-day moving average price is $21.
54 and its two-hundred day moving average price is $26.35. Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) last issued its earnings results on Thursday, February 27th.
The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.
08. As a group, equities analysts forecast that Spyre Therapeutics, Inc. will post -4.
46 EPS for the current year. Analyst Ratings ChangesSYRE has been the topic of several recent research reports. The Goldman Sachs Group upgraded Spyre Therapeutics to a “strong-buy” rating in a report on Tuesday, February 18th.
Wedbush reiterated an “outperform” rating and issued a $65.00 price target on shares of Spyre Therapeutics in a report on Monday, January 13th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company.
According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $54.83.
Check Out Our Latest Research Report on Spyre TherapeuticsSpyre Therapeutics Profile (Free Report)Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).Featured StoriesFive stocks we like better than Spyre TherapeuticsHow to Start Investing in Real EstateRubrik Stock’s V-Bottom Reversal Signals a Major Rally AheadHow to Calculate Options ProfitsHow Super Micro Computer Stock Is Defying the Market Sell-OffHow Investors Can Find the Best Cheap Dividend StocksAppLovin vs.
HPE: Which Tech Stock Can Bounce Back Faster?Want to see what other hedge funds are holding SYRE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report).
.
